New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:16 EDTNLNKOn The Fly: Pre-market Movers
Subscribe for More Information
08:27 EDTNLNKNewLink Genetics falls after Ebola vaccine trial suspended
Shares of NewLink Genetics (NLNK) are falling in pre-market trading after a clinical trial of the Ebola vaccine being developed by the company and partner Merck (MRK) was temporarily suspended as a precautionary measure after four patients complained of joint pains in their hands and feet, the University of Geneva Hospital said. The trials are scheduled to resume next month in up to 15 volunteers after checks to make sure that the joint pain symptoms were benign and temporary, the hospital added. Shares of NewLink are down 6.5% to $34.50 in early morning trading following the news, while Merck shares are indicated to open fractionally higher.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use